Daniel H van Raalte (Daniel van Raalte, Daniël H van Raalte)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 18

Top Topics

Angiotensin Converting Enzyme

Top Venues

Diabetes, obesity & metabolism

Nephrology (Carlton, Vic.)

This page only lists publications with an associated author ORCID identifier.

Publications

Coco M Fuhri Snethlage, Manon Balvers, Bart Ferwerda, Elena Rampanelli, Pleun de Groen, Bart O Roep, Hilde J Herrema, Timothy James McDonald, Daniel H van Raalte, Michael N Weedon, Richard D Oram, Max Nieuwdorp, Nordin M J Hanssen
Associations between diabetes-related genetic risk scores and residual beta cell function in type 1 diabetes: the GUTDM1 study. Diabetologia (2024)
Douwe F de Wit, Coco M Fuhri Snethlage, Elena Rampanelli, Kim Maasen, Noortje Walpot, Daniel H van Raalte, Max Nieuwdorp, Maarten R Soeters, Nordin M J Hanssen
Higher fibre and lower carbohydrate intake are associated with favourable CGM metrics in a cross-sectional cohort of 470 individuals with type 1 diabetes. Diabetologia (2024)
Rosalie A Scholtes, Anne C Hesp, Charlotte M Mosterd, Frank Geurts, Ewout J Hoorn, Daniel J Touw, Merle M Krebber, Jaap A Joles, Hiddo J Lambers Heerspink, Daniel H van Raalte
Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People With Type 2 Diabetes. Circulation 146 (24) (2022)
Rosalie A Scholtes, Anne C Hesp, Charlotte M Mosterd, Frank Geurts, Ewout J Hoorn, Daniel J Touw, Merle M Krebber, Jaap A Joles, Hiddo J Lambers Heerspink, Daniel H van Raalte
Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People With Type 2 Diabetes. Circulation 146 (24) (2022)
Steven E Kahn, Yi-Chun Chen, Nathalie Esser, Austin J Taylor, Daniel H van Raalte, Sakeneh Zraika, C Bruce Verchere
The β Cell in Diabetes: Integrating Biomarkers With Functional Measures. Endocrine reviews 42 (5) (2022)
Rosalie A Scholtes, Anne C Hesp, Charlotte M Mosterd, Frank Geurts, Ewout J Hoorn, Daniel J Touw, Merle M Krebber, Jaap A Joles, Hiddo J Lambers Heerspink, Daniel H van Raalte
Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People With Type 2 Diabetes. Circulation 146 (24) (2022)
Daan M van Velzen, Chantal Maria Wiepjes, Nienke M Nota, Daniel H van Raalte, Renée de Mutsert, Suat Simsek, Martin den Heijer
Incident Diabetes Risk Is Not Increased in Transgender Individuals Using Hormone Therapy. The Journal of clinical endocrinology and metabolism 107 (5) (2022)
Rosalie A Scholtes, Michaël J B van Baar, Megan D Kok, Petter Bjornstad, David Z I Cherney, Jaap A Joles, Daniel H van Raalte
Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors. Nephrology (Carlton, Vic.) 26 (5) (2021)
Charlotte C van Ruiten, Annemarie B van der Aart-van der Beek, Richard G IJzerman, Max Nieuwdorp, Klaas Hoogenberg, Daniel H van Raalte, Hiddo J Lambers Heerspink
Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial. Diabetes, obesity & metabolism 23 (8) (2021)
Rosalie A Scholtes, Michaël J B van Baar, Yuliya Lytvyn, Petter Bjornstad, Max Nieuwdorp, David Z I Cherney, Daniel H van Raalte
Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both? Diabetes, obesity & metabolism (2020)
Linda T Muijs, Caterina Racca, Maartje de Wit, Annelies Brouwer, Thomas H Wieringa, Ralph de Vries, Erik H Serné, Daniel H van Raalte, Femke Rutters, Frank J Snoek
Glucose variability and mood in adults with diabetes: A systematic review. Endocrinology, diabetes & metabolism 4 (1) (2020)
Karlinde A Spit, Marcel H A Muskiet, Lennart Tonneijck, Mark M Smits, Mark H H Kramer, Jaap A Joles, Anneloes de Boer, Daniel H van Raalte
Renal sinus fat and renal hemodynamics: a cross-sectional analysis. Magma (New York, N.Y.) 33 (1) (2019)
Danii Ls Suijk, Mark M Smits, Marcel Ha Muskiet, Lennart Tonneijck, Mark Hh Kramer, Jaap A Joles, Daniel H van Raalte
Plasma uric acid and renal haemodynamics in type 2 diabetes patients. Nephrology (Carlton, Vic.) 25 (4) (2019)
Rosalie A Scholtes, Daniel H van Raalte, Ricardo Correa-Rotter, Robert D Toto, Hiddo J Lambers Heerspink, Valerie Cain, C David Sjöström, Peter Sartipy, Bergur V Stefánsson
The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis. Diabetes, obesity & metabolism 22 (4) (2019)
Anna L Emanuel, Nicolien C de Clercq, Annefleur M Koopen, Erik van Poelgeest, Mireille J M Serlie, Daniel H van Raalte, Mark H H Kramer, Max Nieuwdorp, Etto C Eringa, Erik H Serné
Iloprost infusion prevents the insulin-induced reduction in skeletal muscle microvascular blood volume but does not enhance peripheral glucose uptake in type 2 diabetic patients. Diabetes, obesity & metabolism 20 (11) (2018)
Lennart Tonneijck, Marcel H A Muskiet, Mark M Smits, Petter Bjornstad, Mark H H Kramer, Michaela Diamant, Ewout J Hoorn, Jaap A Joles, Daniel H van Raalte
Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials. Diabetes, obesity & metabolism 20 (5) (2018)
Daniel H van Raalte, C Bruce Verchere
Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest? Diabetes, obesity & metabolism 19 (9) (2017)
Lennart Tonneijck, Marcel H A Muskiet, Mark M Smits, Trynke Hoekstra, Mark H H Kramer, A H Jan Danser, Michaela Diamant, Jaap A Joles, Daniel H van Raalte
Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial. Diabetes, obesity & metabolism 19 (12) (2017)